MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
1.208
-0.003
-0.21%
Opening 09:55 10/04 EDT
OPEN
1.200
PREV CLOSE
1.210
HIGH
1.208
LOW
1.170
VOLUME
116.66K
TURNOVER
120.00K
52 WEEK HIGH
5.79
52 WEEK LOW
0.8801
MARKET CAP
242.97M
P/E (TTM)
-6.9838
1D
5D
1M
3M
1Y
5Y
Summit Therapeutics Seeks Partnership For Phase 3 Infection Candidate Development
In an SEC filing, Summit Therapeutics Inc (NASDAQ: SMMT) said it would seek partners or divestiture of ridinilazole as the path forward for the clinical development of the asset. 
Benzinga · 4h ago
Summit Therapeutics slips on plans to terminate study for lead candidate
Summit Therapeutics (NASDAQ:SMMT), a biotech focused on ...
Seekingalpha · 7h ago
BRIEF-Summit Therapeutics Will Seek Partners Or Divestiture Of Ridinilazole As Path Forward For Clinical Development Of Asset
BRIEF-Summit Therapeutics Will Seek Partners Or Divestiture Of Ridinilazole As Path Forward For Clinical Development Of Asset
Reuters · 7h ago
Summit Therapeutics Will Discontinue Its Only Active Study For Ridinilazole, A Pediatric Clinical Trial Evaluating Ridinilazole For Treating Adolescent Patients With CDI
- Reuters 
Benzinga · 7h ago
Summit Therapeutics On September 28, 2022, Determined That It Will Seek Partners Or A Divestiture Of Ridinilazole As The Path Forward For The Clinical Development Of The Asset; For The Treatment Of Patients With Clostridioide Difficile Infection
- Reuters 
Benzinga · 8h ago
BRIEF-Summit Therapeutics Appoints Dr. Robert Booth To Board
BRIEF-Summit Therapeutics Appoints Dr. Robert Booth To Board
Reuters · 23h ago
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers CinCor Pharma (NASDAQ:CINC) shares moved upwards by 19.5% to $33.0 during Tuesday's after-market session. The market value of their outstanding shares is at $1.4 billion.
Benzinga · 09/20 21:35
How Is The Market Feeling About Summit Therapeutics?
Summit Therapeutics's (NASDAQ:SMMT) short percent of float has fallen 80.59% since its last report. The company recently reported that it has 845 thousand shares sold short, which is 0.66% of all regular shares that are available for trading.
Benzinga · 08/25 13:05
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antibiotics for serious infectious diseases. Its lead CDI product candidate is ridinilazole is an orally administered small molecule antibiotic. The Company's preclinical candidates include SMT-738, from the DDS-04 series for development in the fight against multidrug-resistant infections, specifically carbapenem-resistant Enterobacteriaceae (CRE) infections. The Company is conducting a Phase III clinical program, which is focused on treating patients suffering from Clostridioides difficile infection, also known as C. difficile infection (CDI). The Company is also seeking to expand its product candidate portfolio through the development of a new mechanism, precision antibiotics using its Discuva Platform.

Webull offers kinds of Summit Therapeutics Inc stock information, including NASDAQ:SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.